Welcome to our dedicated page for Neuberger Berman High Yield Strategies SEC filings (Ticker: NHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering whether Neuberger Berman High Yield Strategies Fund (NHS) can keep covering its monthly payout? Most investors start with the annual report yet soon discover page after page of credit tables and leverage footnotes. Our platform answers those questions in minutes.
Use Stock Titan to jump straight to what matters in every NHS filing. From the N-CSR that details distribution coverage to the 8-K material events explained, our AI-powered summaries translate technical language into plain English. You’ll see credit-rating shifts, leverage-cost trends and portfolio turnover without reading the entire document.
Need the latest moves by portfolio managers? The Neuberger Berman High Yield Strategies Fund insider trading Form 4 transactions feed shows executive stock trades as they hit EDGAR. Curious about quarterly results? The NHS quarterly earnings report 10-Q filing is parsed instantly, highlighting net investment income and unrealized gains. Our coverage spans every form:
- NHS executive stock transactions Form 4 (real-time alerts)
- NHS annual report 10-K simplified with AI commentary
- Current reports—NHS 8-K material events explained
- Proxy statement for NHS executive compensation
Each document arrives on Stock Titan seconds after EDGAR posts. Our expert analysis layers context, compares past periods and flags red-line changes. Whether you’re monitoring high-yield credit exposure, tracking distribution sustainability, or simply looking for understanding NHS SEC documents with AI, this is your single stop.
Form 4 highlights: On 07/17/2025, portfolio manager Chris Kocinski purchased 6,000 common shares of Neuberger Berman High Yield Strategies Fund Inc. (NHS) at a volume-weighted average price of $7.3995 (price range $7.395-$7.41). This was an open-market “P” code transaction and no shares were sold.
Following the trade, Kocinski’s direct beneficial ownership rose to 21,000 shares. No derivative securities were involved and there were no amendments to prior filings. The transaction suggests incremental insider confidence but represents a modest dollar amount (~$44k) relative to the fund’s market capitalization.
Neuberger Berman High Yield Strategies Fund (NYSE:NHS) submitted a routine monthly Form NPORT-P on 29 June 2025. The public version lists required data fields—assets, liabilities, risk metrics (DV01/DV100, credit-spread exposure), securities-lending activity, monthly fund returns, and share flows—but most numeric details are either redacted or reported at the individual-security level. No narrative, risk factors, legal proceedings, or management commentary accompany the filing, and no aggregate financial highlights are provided.
Because NPORT-P reports are primarily informational and the disclosed figures are limited, this filing does not reveal any material changes to NHS’s strategy, leverage, or financial condition that would meaningfully affect investor sentiment.
FAQ
What is the current stock price of Neuberger Berman High Yield Strategies (NHS)?
What is the market cap of Neuberger Berman High Yield Strategies (NHS)?
